ImmunityBio, Inc. IBRX Segment Reporting — Impairment of intangible assets
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill.
The official record: ImmunityBio, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s segment reporting — impairment of intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s segment reporting — impairment of intangible assets?
- ImmunityBio, Inc. (IBRX) reported segment reporting — impairment of intangible assets of $0 in Q4 2025.
- What is the long-term trend for ImmunityBio, Inc.'s segment reporting — impairment of intangible assets?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s segment reporting — impairment of intangible assets has grown at a -100.0% compound annual growth rate (CAGR), from $681K to $0.
- What does segment reporting — impairment of intangible assets mean?
- This metric represents the non-cash charge recognized when the carrying value of an intangible asset exceeds its fair value. It reflects a downward adjustment in the valuation of assets such as patents, licenses, or acquired intellectual property within a specific business segment. Frequent impairment charges may indicate overvaluation of acquired assets or a decline in the commercial viability of the segment's pipeline.